Summary & Overview
HCPCS J2062: Loxapine Inhalation, 1 mg
HCPCS Level II code J2062 designates loxapine for inhalation, 1 mg — an inhaled antipsychotic used for acute management of agitation in psychiatric settings. Nationally, this code captures the supply and drug component for delivering rapid-onset inhaled loxapine in acute care environments, making it relevant for hospitals, emergency departments, and inpatient psychiatric units that treat agitation in patients with schizophrenia or bipolar disorder.
Key payers covered in standard analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for inhaled loxapine, typical sites of service, and the role of the code in billing for drug administration in acute behavioral health episodes. The publication outlines common modifiers used with drug supply codes (listed separately), payer coverage considerations, and coding relationships important for claims processing.
This report also summarizes what to expect in reimbursement benchmarking and policy updates affecting inhaled antipsychotic drugs, and it highlights operational considerations for coding and service-line alignment. Data not available in the input for specific utilization rates, associated ICD-10 diagnoses, and taxonomy mappings is noted where applicable.
Billing Code Overview
HCPCS Level II code J2062 represents loxapine for inhalation, 1 mg. This entry describes a single-dose inhaled formulation of loxapine, an antipsychotic medication delivered via inhalation for the acute management of agitation associated with schizophrenia or bipolar disorder.
Service Type: Acute inhalation medication administration
Typical Site of Service: Hospital emergency department, inpatient psychiatric unit, observation unit, or other acute care setting where inhaled pharmacologic treatment for agitation is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute agitation or severe agitation associated with schizophrenia or bipolar disorder who requires rapid administration of an antipsychotic and is able to use an inhalation device. The presenting workflow commonly occurs in an emergency department, urgent behavioral health clinic, psychiatric observation unit, or inpatient psychiatric unit. Initial triage documents safety risk and medical stability; nursing performs baseline vital signs and contraindication screening (notably respiratory disease). A clinician orders J2062 (loxapine for inhalation, 1 mg) with route and number of inhalations. The medication is administered via a single-use inhalation device by trained staff; monitoring includes continuous pulse oximetry for respiratory status and observation for sedation, extrapyramidal symptoms, or chest discomfort. If inhalation is successful and agitation is controlled, the patient proceeds to ongoing psychiatric evaluation and disposition planning. If inhalation is contraindicated or ineffective, alternate parenteral antipsychotic therapy or de-escalation measures are used.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard claim | Use when no specific modifier applies to the service. |
| 22 | Increased procedural services | Use when administration required substantially greater resources or time than typical (rare for medication administration).